HSE to fund on limited basis cost of multiple sclerosis drug

Stuart SchlossmanFor the Benefit of the Patient, MS Drug Therapies, Multiple Sclerosis

Extended campaign by patients proves success for medicine that helps sufferers to walk

Patients have been paying up to €500 a month for Fampridine from their own resources. Photograph: Getty Images

Patients have been paying up to €500 a month for Fampridine from their own resources. Photograph: Getty Images

Sept 3, 2015  –  The Health Service Executive has agreed to fund on a limited basis the cost of a drug that helps people with multiple sclerosis to walk.
The announcement that Fampridine (known commercially as Fampyra) is to be reimbursed under the State-funded drugs schemes follows a lengthy campaign by patients who says the drug has greatly aided their mobility.
The HSE says it is in the final stages of putting in place the arrangement around a “responder-based” reimbursement programme for Fampridine.

~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
MS Views and News helps to provide information for all affected by MS
Keep up to date with the news and information we provide 
by signing up by clicking here
.=====================================================
Visit our MS Learning Channel on YouTube: http://www.youtube.com/msviewsandnews